Given the consistent phenotypes observed in both CRC cell types, we postulated that elesclomol‐induced downregulation of ATP7A, but not ATP7B, is responsible for copper retention and consequent antitumour activity of elesclomol. This evidence concerns the gene ATP7A and colorectal carcinoma.